成纤维细胞生长因子21与妊娠期代谢性疾病的研究进展

doi:10.12280/gjfckx.20230156

摘要/Abstract

摘要：

妊娠期代谢性疾病（gestational metabolic diseases，GMD）是影响孕产妇及新生儿结局最主要的原因，目前其作用机制仍不清楚。成纤维细胞生长因子21（fibroblast growth factor 21，FGF21）是由多种器官合成的多肽激素，其作用机制复杂，在体外和体内调节一系列代谢过程，主要以内分泌方式参与葡萄糖、脂质、能量调节及胆汁酸的肝肠循环等代谢活动，还在细胞增殖与分化、神经元发育、血管生成及伤口愈合过程中发挥关键作用。因此，FGF21的释放障碍、信号失调和功能异常与GMD如妊娠期糖尿病、妊娠期高血压疾病和妊娠期肝内胆汁淤积症等密切相关。综述FGF21在GMD中作用机制的最新研究进展，以期及早、精确地发现GMD及其隐匿病情，达到早诊断、早干预的目的，最终改善母儿预后。

关键词: 成纤维细胞生长因子21, 代谢, 糖尿病, 妊娠, 高血压, 妊娠性, 胆汁淤积, 肝内

Abstract:

Gestational metabolic diseases (GMD) are the most common cause of maternal and neonatal outcomes, but the mechanism remains unclear. Fibroblast growth factor 21 (FGF21) is a polypeptide hormone synthesized by a variety of organs. Its mechanism of action is complex. It regulates a series of metabolic processes in vitro and in vivo, and mainly participates in metabolic activities such as glucose, lipid, energy regulation and hepato-intestinal circulation of bile acid by means of endocrine. It also plays a key role in cell proliferation and differentiation, neuronal development, angiogenesis and wound healing. Therefore, FGF21 release disorders, signal dysregulation, and abnormal function are closely associated with GMD such as gestational diabetes mellitus, gestational hypertension disease, and intrahepatic cholestasis of pregnancy. This article reviews the latest research progress on the mechanism of FGF21 in GMD, so as to identify GMD and its hidden disease as early and accurate as possible, achieve the purpose of early diagnosis and intervention, and ultimately improve the prognosis of mothers and infants.

Key words: Fibroblast growth factor 21, Metabolism, Diabetes, gestational, Hypertension, pregnancy-induced, Cholestasis, intrahepatic

李晶晶, 孙晓彤, 柳婷婷, 李振英, 张一凡, 苏妍. 成纤维细胞生长因子21与妊娠期代谢性疾病的研究进展[J]. 国际妇产科学杂志, 2023, 50(4): 400-404.

LI Jing-jing, SUN Xiao-tong, LIU Ting-ting, LI Zhen-ying, ZHANG Yi-fan, SU Yan. Research Progress of Fibroblast Growth Factor 21 and Gestational Metabolic Diseases[J]. Journal of International Obstetrics and Gynecology, 2023, 50(4): 400-404.

参考文献 35

[1]	周洁, 张玉冬, 刘明. 脂肪因子与2型糖尿病血管病变的研究进展[J]. 血管与腔内血管外科杂志, 2022, 8(2):192-196. doi: 10.19418/j.cnki.issn2096-0646.2022.02.14. doi: 10.19418/j.cnki.issn2096-0646.2022.02.14
[2]	Xie Y, Su N, Yang J, et al. FGF/FGFR signaling in health and disease[J]. Signal Transduct Target Ther, 2020, 5(1):181. doi: 10.1038/s41392-020-00222-7. doi: 10.1038/s41392-020-00222-7
[3]	Lu W, Li X, Luo Y. FGF21 in obesity and cancer: New insights[J]. Cancer Lett, 2021, 499:5-13. doi: 10.1016/j.canlet.2020.11.026. doi: 10.1016/j.canlet.2020.11.026 pmid: 33264641
[4]	Buchanan S, Combet E, Stenvinkel P, et al. Klotho, Aging, and the Failing Kidney[J]. Front Endocrinol (Lausanne), 2020, 11:560. doi: 10.3389/fendo.2020.00560. doi: 10.3389/fendo.2020.00560
[5]	吕昀, 柳景华. 成纤维细胞生长因子21:参与代谢调节的细胞因子[J]. 生理科学进展, 2011, 42(3):234-237.
[6]	Akkar I, Karaca Z, Taheri S, et al. The stimulatory effects of glucagon on cortisol and GH secretion occur independently from FGF-21[J]. Endocrine, 2022, 75(1):211-218. doi: 10.1007/s12020-021-02829-4. doi: 10.1007/s12020-021-02829-4
[7]	Xiao F, Guo Y, Deng J, et al. Hepatic c-Jun regulates glucose metabolism via FGF21 and modulates body temperature through the neural signals[J]. Mol Metab, 2019, 20:138-148. doi: 10.1016/j.molmet.2018.12.003. doi: S2212-8778(18)30976-1 pmid: 30579932
[8]	Pan Q, Lin S, Li Y, et al. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis[J]. EBioMedicine, 2021, 63:103202. doi: 10.1016/j.ebiom.2020.103202. doi: 10.1016/j.ebiom.2020.103202
[9]	Samms RJ, Smith DP, Cheng CC, et al. Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1[J]. Cell Rep, 2015, 11(7):991-999. doi: 10.1016/j.celrep.2015.04.046. doi: 10.1016/j.celrep.2015.04.046 pmid: 25956583
[10]	Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21):1861-1871. doi: 10.1161/CIRCULATIONAHA.115.015308. doi: 10.1161/CIRCULATIONAHA.115.015308 pmid: 25794851
[11]	Huang Z, Xu A, Cheung B. The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension[J]. Curr Hypertens Rep, 2017, 19(4):28. doi: 10.1007/s11906-017-0730-5. doi: 10.1007/s11906-017-0730-5 pmid: 28337713
[12]	赵晨露, 尚东方, 周铖, 等. 肝因子和脂肪因子介导的脂代谢在非酒精性脂肪性肝病中的作用机制[J]. 临床肝胆病杂志, 2023, 39(1):168-174. doi: 10.3969/j.issn.1001-5256.2023.01.026. doi: 10.3969/j.issn.1001-5256.2023.01.026
[13]	Režen T, Rozman D, Kovács T, et al. The role of bile acids in carcinogenesis[J]. Cell Mol Life Sci, 2022, 79(5):243. doi: 10.1007/s00018-022-04278-2. doi: 10.1007/s00018-022-04278-2 pmid: 35429253
[14]	Smith DD, Rood KM. Intrahepatic Cholestasis of Pregnancy[J]. Clin Obstet Gynecol, 2020, 63(1):134-151. doi: 10.1097/GRF.0000000000000495. doi: 10.1097/GRF.0000000000000495 pmid: 31764000
[15]	Zhang J, Gupte J, Gong Y, et al. Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action[J]. EBioMedicine, 2017, 15:173-183. doi: 10.1016/j.ebiom.2016.12.016. doi: S2352-3964(16)30595-3 pmid: 28041926
[16]	Cariello M, Piglionica M, Gadaleta RM, et al. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism[J]. Handb Exp Pharmacol, 2019, 256:73-93. doi: 10.1007/164_2019_235. doi: 10.1007/164_2019_235 pmid: 31123830
[17]	Chen MM, Hale C, Stanislaus S, et al. FGF21 acts as a negative regulator of bile acid synthesis[J]. J Endocrinol, 2018, 237(2):139-152. doi: 10.1530/JOE-17-0727. doi: 10.1530/JOE-17-0727 pmid: 29615519
[18]	Lorenzo-Almorós A, Hang T, Peiró C, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases[J]. Cardiovasc Diabetol, 2019, 18(1):140. doi: 10.1186/s12933-019-0935-9. doi: 10.1186/s12933-019-0935-9 pmid: 31666083
[19]	Sweeting A, Wong J, Murphy HR, et al. A Clinical Update on Gestational Diabetes Mellitus[J]. Endocr Rev, 2022, 43(5):763-793. doi: 10.1210/endrev/bnac003. doi: 10.1210/endrev/bnac003 pmid: 35041752
[20]	Hu Y, Liu J, Zhang H, et al. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus[J]. Diabetes Metab, 2016, 42(5):358-363. doi: 10.1016/j.diabet.2016.04.005. doi: S1262-3636(16)30397-4 pmid: 27178737
[21]	Porter JW, Rowles JL 3rd, Fletcher JA, et al. Anti-inflammatory effects of exercise training in adipose tissue do not require FGF21[J]. J Endocrinol, 2017, 235(2):97-109. doi: 10.1530/JOE-17-0190. doi: 10.1530/JOE-17-0190 pmid: 28765264
[22]	Wang N, Sun B, Guo H, et al. Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtype: A Case-Control Study[J]. Front Endocrinol (Lausanne), 2021, 12:795520. doi: 10.3389/fendo.2021.795520. doi: 10.3389/fendo.2021.795520
[23]	Ma′ayeh M, Costantine MM. Prevention of preeclampsia[J]. Semin Fetal Neonatal Med, 2020, 25(5):101123. doi: 10.1016/j.siny.2020.101123. doi: 10.1016/j.siny.2020.101123
[24]	Overton E, Tobes D, Lee A. Preeclampsia diagnosis and management[J]. Best Pract Res Clin Anaesthesiol, 2022, 36(1):107-121. doi: 10.1016/j.bpa.2022.02.003. doi: 10.1016/j.bpa.2022.02.003 pmid: 35659948
[25]	Jung E, Romero R, Yeo L, et al. The etiology of preeclampsia[J]. Am J Obstet Gynecol, 2022, 226(2S):S844-S866. doi: 10.1016/j.ajog.2021.11.1356. doi: 10.1016/j.ajog.2021.11.1356 pmid: 35177222
[26]	Xie T, So WY, Li XY, et al. Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism[J]. Clin Sci (Lond), 2019, 133(19):2029-2044. doi: 10.1042/CS20190093. doi: 10.1042/CS20190093 pmid: 31654570
[27]	李彩霞, 贾玉芳, 周琴, 等. FGF21在妊娠期高血压孕妇血清中的表达及意义[J]. 贵州医药, 2022, 46(1):17-19. doi: 10.3969/j.issn.1000-744X.2022.01.005. doi: 10.3969/j.issn.1000-744X.2022.01.005
[28]	Dekker Nitert M, Scholz-Romero K, Kubala MH, et al. Placental fibroblast growth factor 21 is not altered in late-onset preeclampsia[J]. Reprod Biol Endocrinol, 2015, 13:14. doi: 10.1186/s12958-015-0006-3. doi: 10.1186/s12958-015-0006-3
[29]	Jiang L, Zhou Y, Huang Q. Serum fibroblast growth factor 21 level is increased in pre-eclampsia patients: Association with blood pressure and lipid profile[J]. J Obstet Gynaecol Res, 2021, 47(1):375-381. doi: 10.1111/jog.14534. doi: 10.1111/jog.14534
[30]	金嫔嫔, 仇春波, 叶黎霞, 等. 妊娠期肝内胆汁淤积症发生的危险因素和对妊娠结局的影响[J]. 中国妇幼保健, 2021, 36(15):3581-3583. doi: 10.19829/j.zgfybj.issn.1001-4411.2021.15.052. doi: 10.19829/j.zgfybj.issn.1001-4411.2021.15.052
[31]	Ibrahim SH, Jonas MM, Taylor SA, et al. Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant[J]. Hepatology, 2020, 71(4):1474-1485. doi: 10.1002/hep.31109. doi: 10.1002/hep.31109 pmid: 31925801
[32]	Piechota J, Jelski W. Intrahepatic Cholestasis in Pregnancy: Review of the Literature[J]. J Clin Med, 2020, 9(5):1361. doi: 10.3390/jcm9051361. doi: 10.3390/jcm9051361
[33]	McIlvride S, Dixon PH, Williamson C. Bile acids and gestation[J]. Mol Aspects Med, 2017, 56:90-100. doi: 10.1016/j.mam.2017.05.003. doi: S0098-2997(17)30012-2 pmid: 28506676
[34]	李美霖. FGF19、FGF21及共受体KLB在妊娠期肝内胆汁淤积症的表达及意义[D]. 成都: 成都医学院, 2022.
[35]	Kukla M, Kierach R, Skonieczna M, et al. Influence of ursodeoxycholic acid therapy on levels of fibroblast growth factor 21, adiponectin and biochemical parameters in intrahepatic cholestasis of pregnancy[J]. Clin Exp Hepatol, 2021, 7(1):13-24. doi: 10.5114/ceh.2021.104419. doi: 10.5114/ceh.2021.104419